Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume on Earnings Beat

Key Points

• Pharming Group experienced a 57% increase in trading volume following a better-than-expected earnings report, with 8,327 shares traded on Friday.
• The company reported an earnings per share (EPS) of $0.06, surpassing the consensus estimate of ($0.10) by $0.16, along with revenues of $93.20 million beating expectations of $70.36 million.
• An institutional investor, Silverberg Bernstein Capital Management LLC, raised its position in Pharming Group by 8.6%, now owning 52,147 shares valued at approximately $557,000.

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) saw unusually-strong trading volume on Friday following a stronger than expected earnings report. Approximately 8,327 shares were traded during mid-day trading, an increase of 57% from the previous session's volume of 5,289 shares.The stock last traded at $10.60 and had previously closed at $11.11.

The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.16. The business had revenue of $93.20 million for the quarter, compared to analyst estimates of $70.36 million. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company's stock.

Pharming Group Stock Down 0.0%

The stock has a market cap of $839.18 million, a P/E ratio of -94.22 and a beta of 0.02. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38. The stock's fifty day moving average price is $10.74 and its 200 day moving average price is $9.48.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.